Literature DB >> 25022539

Plasma β-amyloid 40 levels are positively associated with mortality risks in the elderly.

Audrey Gabelle1, Susanna Schraen2, Laure-Anne Gutierrez3, Cecile Pays3, Olivier Rouaud4, Luc Buée2, Jacques Touchon3, Catherine Helmer5, Jean-Charles Lambert6, Claudine Berr7.   

Abstract

BACKGROUND: We evaluated if plasma β-amyloid (Aβ) levels were associated with mortality risks in a subsample of the French Three-City (3C) prospective cohort study.
METHODS: Analyses were based on 1254 participants randomly selected from the initial 3C cohort stratified by center, sex, and age in the context of a nested case-cohort study to investigate biological variables. Associations between plasma Aβ and mortality were assessed with the Cox regression model with delayed entry including various potential confounding factors and testing possible mediators.
RESULTS: A relationship between high plasma Aβ1-40 concentrations and risk of mortality (hazards ratio, 1.15; 95% confidence interval, 1.01-1.31, P = .03) was unveiled independently of age, educational level, vascular risk factors, diet, physical activity, cognitive impairment, or frailty status. It was only modified when we included cystatin C levels.
CONCLUSIONS: Further investigations are needed to determine precisely the pathophysiological roles of plasma Aβ1-40 and cystatin C and before envisioning any future clinical applications.
Copyright © 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aging; Cystatin C; Frailty; Mild cognitive impairment due to Alzheimer's disease; Mortality risks; Plasma amyloid markers

Mesh:

Substances:

Year:  2014        PMID: 25022539     DOI: 10.1016/j.jalz.2014.04.515

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  7 in total

1.  Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study.

Authors:  Xiuzhe Wang; Erik Hjorth; Inger Vedin; Maria Eriksdotter; Yvonne Freund-Levi; Lars-Olof Wahlund; Tommy Cederholm; Jan Palmblad; Marianne Schultzberg
Journal:  J Lipid Res       Date:  2015-01-23       Impact factor: 5.922

2.  Relationship between frailty and Alzheimer's disease biomarkers: A scoping review.

Authors:  Lindsay Wallace; Olga Theou; Kenneth Rockwood; Melissa K Andrew
Journal:  Alzheimers Dement (Amst)       Date:  2018-05-30

3.  CSF level of β-amyloid peptide predicts mortality in Alzheimer's disease.

Authors:  Adla Boumenir; Emmanuel Cognat; Severine Sabia; Claire Hourregue; Matthieu Lilamand; Aline Dugravot; Elodie Bouaziz-Amar; Jean-Louis Laplanche; Jacques Hugon; Archana Singh-Manoux; Claire Paquet; Julien Dumurgier
Journal:  Alzheimers Res Ther       Date:  2019-03-28       Impact factor: 6.982

Review 4.  What Is the Molecular Signature of Mind-Body Interventions? A Systematic Review of Gene Expression Changes Induced by Meditation and Related Practices.

Authors:  Ivana Buric; Miguel Farias; Jonathan Jong; Christopher Mee; Inti A Brazil
Journal:  Front Immunol       Date:  2017-06-16       Impact factor: 7.561

5.  Meditation and vacation effects have an impact on disease-associated molecular phenotypes.

Authors:  E S Epel; E Puterman; J Lin; E H Blackburn; P Y Lum; N D Beckmann; J Zhu; E Lee; A Gilbert; R A Rissman; R E Tanzi; E E Schadt
Journal:  Transl Psychiatry       Date:  2016-08-30       Impact factor: 6.222

6.  Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta-analyses.

Authors:  Falah Alhajraf; Deborah Ness; Abdul Hye; Andre Strydom
Journal:  Dev Neurobiol       Date:  2019-09-11       Impact factor: 3.964

7.  Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals.

Authors:  Sylvain Lehmann; Julien Dumurgier; Xavier Ayrignac; Cecilia Marelli; Daniel Alcolea; Juan Fortea Ormaechea; Eric Thouvenot; Constance Delaby; Christophe Hirtz; Jérôme Vialaret; Nelly Ginestet; Elodie Bouaziz-Amar; Jean-Louis Laplanche; Pierre Labauge; Claire Paquet; Alberto Lleo; Audrey Gabelle
Journal:  Alzheimers Res Ther       Date:  2020-10-02       Impact factor: 6.982

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.